BABEL is an observational, single-center, prospective study about patients affected by biliary tract cancers (BTC) treated at the Medical Oncology Unit of the FPUAG - IRCCS.
BABEL is an observational, single-center, prospective study with an historical cohort. Study population is represented by patients affected by biliary tract cancers (BTC) treated at the Medical Oncology Unit of the FPUAG - IRCCS. The study involves an historical cohort and a prospective cohort. Primary aim of the study is to associate BTC patients' overall survival with IDH1/2 mutations, in order to confirm the prognostic role of these genes both metastatic and resectable disease setting. The secondary aims are to correlate FGFR mutations and overall survival of BTC patients and to find new clinical and molecular characteristics linked with survival and response to treatment.
Study Type
OBSERVATIONAL
Enrollment
560
Fondazione Policlinico Universitario Agostino Gemelli/IRCSS - UOC di Oncologia Medica
Roma, Rome, Italy
RECRUITINGOverall survival
OS is defined as the time between patient's date of diagnosis and date of death from any cause of the patient. For patients with no observed event, the follow-up time will be ended to the same date.
Time frame: The expected OS for BTC patients is 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.